The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).
 
Giovanni Scambia
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro
Speakers' Bureau - Clovis Oncology; MSD
 
Francesco Raspagliesi
Honoraria - GlaxoSmithKline; MSD Oncology
Consulting or Advisory Role - AstraZeneca/Merck (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Giorgio Valabrega
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; MSD; PharmaMar
Research Funding - Clovis Oncology (Inst)
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
 
Carmen Pisano
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - AstraZeneca/Merck; GlaxoSmithKline; PharmaMar
 
Chiara Cassani
No Relationships to Disclose
 
Germana Tognon
No Relationships to Disclose
 
Stefano Tamberi
No Relationships to Disclose
 
Giorgia Mangili
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; MSD; PharmaMar
Travel, Accommodations, Expenses - MSD
 
Serafina Mammoliti
No Relationships to Disclose
 
Ugo De Giorgi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck; MSD; Novartis; Pfizer; PharmaMar
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Filippo Greco
No Relationships to Disclose
 
Anna Maria Mosconi
No Relationships to Disclose
 
Enrico Breda
No Relationships to Disclose
 
Grazia Artioli
Speakers' Bureau - GlaxoSmithKline; MSD; PharmaMar
 
Claudia Andreetta
Honoraria - Bristol-Myers Squibb (I); Merck (I); MSD (I); Novartis (I); Pierre Fabre (I); Sanofi (I); Sun Pharma (I)
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; PharmaMar
 
Claudia Casanova
No Relationships to Disclose
 
Rita Ceccherini
No Relationships to Disclose
 
Antonio Frassoldati
No Relationships to Disclose
 
Domenica Lorusso
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; Merck Serono; MSD; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; GlaxoSmithKline; PharmaMar; Roche
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup